Cargando…
Was the implementation strategy of the ProACT trial adequately proactive?
The ProACT trial does not inform the evidence base regarding safety and clinical effectiveness of procalcitonin (PCT) as a biomarker to guide antibiotic administration for LRTIs, but reveals potential challenges in the introduction of PCT in real life. http://ow.ly/Enfr30n2TK6
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Respiratory Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395982/ https://www.ncbi.nlm.nih.gov/pubmed/30838064 http://dx.doi.org/10.1183/20734735.0338-2018 |
| Sumario: | The ProACT trial does not inform the evidence base regarding safety and clinical effectiveness of procalcitonin (PCT) as a biomarker to guide antibiotic administration for LRTIs, but reveals potential challenges in the introduction of PCT in real life. http://ow.ly/Enfr30n2TK6 |
|---|